PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) , a developer of novel pharmaceutical and dermaceutical products, announced today the commercial launch of its Nurigene skin care line, a scientifically advanced skin care regimen. The Nurigene products leverage Avicena's proprietary cellular energy technology to achieve significant anti-aging benefits by enhancing the skin's ability to regenerate and protect itself. Clinical studies have demonstrated that the Nurigene skin care regimen offers multiple anti-aging benefits including improvements in skin cell turnover, skin firmness, skin elasticity and the skin's ability to retain moisture. Results showed that skin treated with the Nurigene skin care regimen had a statistically significant increase in cell turnover of up to 43%, effectively encouraging younger skin cells to reach the surface. In addition, results demonstrated that the Nurigene skin care regimen produced a statistically significant increase in skin firmness and elasticity. Findings also demonstrated that Nurigene led to statistically significant improvements in skin barrier function, effectively increasing in the skin's ability to retain moisture. "The Nurigene skin care regimen has demonstrated outstanding anti-aging benefits and has garnered very positive feedback from consumers," said Belinda Tsao Nivaggioli, Ph.D., Avicena's Chairman and Chief Executive Officer. "By applying our proprietary technology platform to the development of next-generation dermaceuticals, we are able to tap into the growing $9 billion U.S. skin care market. By developing this skin care regimen, we have created a product line that truly meets women's skin health needs, while demonstrating our ability to develop and commercialize products based on our cellular energy platform." ABOUT NURIGENE(TM) The Nurigene product line is a scientifically based line of skin care products formulated to achieve significant anti-aging benefits by enhancing the regeneration of healthier-looking skin and protecting against damaging free radicals. The product line incorporates the Company's proprietary Advanced Skin Nourishment(TM) technology, which is designed to promote optimal cellular regeneration and protection by providing critical nourishment to skin cells. For more information, visit http://www.nurigene.com/. ABOUT AVICENA(TM) Avicena Group, Inc. (OTC:AVGO) (BULLETIN BOARD: AVGO) is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers. SAFE HARBOR This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the Company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the Company's need for additional funds, the Company's dependence on a limited number of therapeutic compounds, the stage of the products the Company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the Company's ability to avoid infringement of the patent rights of others, and the Company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise. DATASOURCE: Avicena Group, Inc. CONTACT: Investors, Sara Ephraim, +1-646-536-7002, , or Media, Janine McCargo, +1-646-536-7033, , or Jason Rando, +1-646-536-7025, , all of The Ruth Group, for Avicena Group, Inc. Web site: http://www.nurigene.com/

Copyright